[F&N] QoQ Cumulative Quarter Result on 30-Jun-2017 [#3]

Stock
[F&N] FRASER & NEAVE HOLDINGS BHD
Announcement Date
03-Aug-2017
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2017
Quarter
30-Jun-2017 [#3]
Profit Trend
QoQ- 29.6%
YoY- -9.55%
Quarter Report
Latest QR
Upcoming QR
F&N's Result
F&N's Financial Summary
View:
Show?
Cumulative Result
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
Revenue 2,083,472 1,068,930 4,101,374 3,125,099 2,083,822 1,091,083 4,167,567 -37.03%
PBT 216,043 115,132 353,713 334,323 260,795 144,007 442,937 -38.06%
Tax -16,662 -8,307 -30,366 -30,611 -26,447 -16,732 -57,567 -56.27%
NP 199,381 106,825 323,347 303,712 234,348 127,275 385,370 -35.57%
-
NP to SH 199,399 106,834 323,377 303,729 234,357 127,278 385,372 -35.57%
-
Tax Rate 7.71% 7.22% 8.58% 9.16% 10.14% 11.62% 13.00% -
Total Cost 1,884,091 962,105 3,778,027 2,821,387 1,849,474 963,808 3,782,197 -37.18%
-
Net Worth 2,203,753 2,225,717 2,130,818 2,110,210 2,154,561 2,140,871 1,987,168 7.14%
Dividend
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
Div 98,839 - 210,518 98,916 98,933 - 210,427 -39.60%
Div Payout % 49.57% - 65.10% 32.57% 42.22% - 54.60% -
Equity
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
Net Worth 2,203,753 2,225,717 2,130,818 2,110,210 2,154,561 2,140,871 1,987,168 7.14%
NOSH 366,778 366,778 366,778 366,778 366,778 366,778 366,778 0.00%
Ratio Analysis
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
NP Margin 9.57% 9.99% 7.88% 9.72% 11.25% 11.67% 9.25% -
ROE 9.05% 4.80% 15.18% 14.39% 10.88% 5.95% 19.39% -
Per Share
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
RPS 569.14 292.00 1,120.23 853.02 568.69 298.14 1,138.80 -37.04%
EPS 54.50 29.20 88.30 82.90 64.00 34.80 105.30 -35.56%
DPS 27.00 0.00 57.50 27.00 27.00 0.00 57.50 -39.61%
NAPS 6.02 6.08 5.82 5.76 5.88 5.85 5.43 7.12%
Adjusted Per Share Value based on latest NOSH - 366,778
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
RPS 568.05 291.44 1,118.22 852.04 568.14 297.48 1,136.26 -37.03%
EPS 54.36 29.13 88.17 82.81 63.90 34.70 105.07 -35.57%
DPS 26.95 0.00 57.40 26.97 26.97 0.00 57.37 -39.59%
NAPS 6.0084 6.0683 5.8096 5.7534 5.8743 5.837 5.4179 7.14%
Price Multiplier on Financial Quarter End Date
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
Date 30/03/18 29/12/17 29/09/17 30/06/17 31/03/17 30/12/16 30/09/16 -
Price 33.38 27.00 24.66 25.30 24.68 23.48 24.06 -
P/RPS 5.86 9.25 2.20 2.97 4.34 7.88 2.11 97.70%
P/EPS 61.28 92.52 27.92 30.52 38.59 67.51 22.85 93.14%
EY 1.63 1.08 3.58 3.28 2.59 1.48 4.38 -48.29%
DY 0.81 0.00 2.33 1.07 1.09 0.00 2.39 -51.42%
P/NAPS 5.54 4.44 4.24 4.39 4.20 4.01 4.43 16.09%
Price Multiplier on Announcement Date
31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 30/09/16 CAGR
Date 03/05/18 06/02/18 07/11/17 03/08/17 03/05/17 07/02/17 03/11/16 -
Price 35.64 29.66 25.44 24.82 24.88 23.66 24.30 -
P/RPS 6.26 10.16 2.27 2.91 4.37 7.94 2.13 105.31%
P/EPS 65.43 101.63 28.80 29.94 38.90 68.03 23.08 100.43%
EY 1.53 0.98 3.47 3.34 2.57 1.47 4.33 -50.05%
DY 0.76 0.00 2.26 1.09 1.09 0.00 2.37 -53.18%
P/NAPS 5.92 4.88 4.37 4.31 4.23 4.04 4.48 20.43%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment